A paper recently published in JAMA Ophthalmology by Hathaway and colleagues at Harvard suggested a potential association between prescribed semaglutide and an increased risk for nonarteritic anterior ischemic optic neuropathy.
Semaglutide is a GLP-1 receptor agonist primarily used as a treatment for diabetes (Ozempic, Novo Nordisk) and more recently greenlit as a breakthrough treatment for obesity (Wegovy, Novo Nordisk). In both conditions, it has shown remarkable effectiveness, with the added benefit of lowering the risk for heart attack and stroke. Understandably, the study findings spread